Spacer use in older adults with COPD or asthma on triple therapy
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether using a spacer with your inhaler can lower the risk of serious flare-ups for people over 65 who have COPD or asthma and are already on triple therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years or older.
- You have been diagnosed with COPD or asthma.
- You've been using a triple inhaler (ICS/LABA/LAMA) for at least 4 weeks.
- In the last year, you've had at least 1 hospital stay or 2 moderate flare-ups due to your lung condition.
- You can learn to use the inhaler properly and give your consent.
- You are not currently using a spacer regularly or have used one for more than 3 weeks in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an emergency-use spacer works as well as a traditional spacer for delivering asthma medication through an inhaler. It may help people with mild to moderate asthma breathe better during an attack.
This trial tests a triple combination inhaler (anti-inflammatory plus two bronchodilators) to see if it can improve lung function in people who are showing early signs of chronic lung damage. It might help if you are a smoker with breathing symptoms and your test shows slightly reduced lung function.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) to see if it can help protect the heart and lungs in people with COPD who also have heart problems or high risk for them.
This study compares a three-in-one inhaler (ICS/LABA/LAMA) to a two-in-one inhaler (ICS/LABA) for adults whose asthma is not well-controlled despite using a standard two-in-one inhaler. The goal is to see if the triple inhaler improves asthma control better.
This study tests whether switching to a higher-dose or extrafine triple inhaler helps people whose asthma is still uncontrolled on their current medium-dose combination inhaler. It focuses on improving small-airway function, which may lead to better symptom control.
This study looks at how often heart problems or stroke happen in people with COPD after they start a specific “triple therapy” inhaler. It may help doctors understand whether these inhalers change cardiovascular (heart) or cerebrovascular (stroke) risk.
Hear when a new Asthma COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.